180916-16-9 Usage
Description
Lasofoxifene, a next-generation selective estrogen receptor modulator, is an off-white solid with significant pharmaceutical applications. It is designed to treat disorders associated with increased bone turnover and osteopenia, making it a valuable compound in the medical field.
Uses
Used in Pharmaceutical Industry:
Lasofoxifene is used as a therapeutic agent for treating disorders associated with increased bone turnover and osteopenia. Its selective estrogen receptor modulating properties help in managing these conditions effectively.
Additionally, due to its estrogen receptor modulating capabilities, Lasofoxifene may also have potential applications in other areas such as treating osteoporosis or certain types of cancer. However, further research and clinical trials would be necessary to confirm these potential uses.
Clinical Use
Lasofoxifene is a very potent second-generation SERM currently in phase III clinical trials for the treatment and
prevention of osteoporosis in postmenopausal women.
Check Digit Verification of cas no
The CAS Registry Mumber 180916-16-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,8,0,9,1 and 6 respectively; the second part has 2 digits, 1 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 180916-16:
(8*1)+(7*8)+(6*0)+(5*9)+(4*1)+(3*6)+(2*1)+(1*6)=139
139 % 10 = 9
So 180916-16-9 is a valid CAS Registry Number.
InChI:InChI=1/C28H31NO2/c30-24-11-15-27-23(20-24)10-14-26(21-6-2-1-3-7-21)28(27)22-8-12-25(13-9-22)31-19-18-29-16-4-5-17-29/h1-3,6-9,11-13,15,20,26,28,30H,4-5,10,14,16-19H2/t26-,28+/m1/s1
180916-16-9Relevant articles and documents
LASOFOXIFENE MODULATION OF MEMBRANE-INITIATED ESTROGEN SIGNALS AND METHODS FOR TUMOR TREATMENT
-
, (2018/08/03)
The present invention found that lasofoxifene is an antagonist of ER-α36. It not only inhibits the growth of ER-α36 positive lung, colon and gastric cancers, and also it can inhibit the growth of acquired or de novo tamoxifen-resistant MCF-7 cells. Our finding also provides methods and compositions for treating cancer comprising lasofoxifene alone or in combination with at least one other agent selected from the group consisting of gefitinib and/or trastuzumab or functional equivalent thereof, and an inhibitor in hormonal or epidermal growth factor signal transduction pathways.
PROCESS FOR PRODUCTION OF LASOFOXIFENE OR ANALOGUE THEREOF
-
Page/Page column 21-22; 30, (2008/12/04)
Disclosed is a novel process for production of lasofoxifene, nafoxidine or an analogue thereof, which comprises reduced number of reaction steps, has a high efficiency, and is practically advantageous. For the production of lasofoxifene or an analogue the
Method for manufacturing a low dose pharmaceutical composition having uniform drug distribution and potency
-
, (2008/06/13)
A method for manufacturing a pharmaceutical composition having uniform drug distribution and potency is described which utilizes silicon dioxide to reduce the loss of active ingredient during the manufacturing process. The method is particularly useful for the manufacture of low dosage tablet compositions.